Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Deferred Tax Liability (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $31.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability changed N/A to $31.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $31.7 million, a N/A change, with the full-year FY2024 number at $32.3 million, up 86.29% from a year prior.
  • Non-Current Deferred Tax Liability was $31.7 million for Q3 2025 at Iovance Biotherapeutics, down from $34.7 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $34.7 million in Q2 2025 to a low of $17.3 million in Q4 2023.
  • A 3-year average of $27.5 million and a median of $31.8 million in 2025 define the central range for Non-Current Deferred Tax Liability.
  • Peak YoY movement for Non-Current Deferred Tax Liability: skyrocketed 86.29% in 2024, then fell 4.02% in 2025.
  • Iovance Biotherapeutics' Non-Current Deferred Tax Liability stood at $17.3 million in 2023, then soared by 86.29% to $32.3 million in 2024, then decreased by 2.01% to $31.7 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Non-Current Deferred Tax Liability are $31.7 million (Q3 2025), $34.7 million (Q2 2025), and $32.0 million (Q1 2025).